Liesbet De Bus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liesbet De Bus has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Jan J. De Waele
Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium
12 shared publications - Pieter Depuydt
Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium
9 shared publications - Bram Gadeyne
Department of Intensive Care, Ghent University Hospital, Ghent, Belgium
6 shared publications - Jerina Boelens
Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
4 shared publications - Jerina Boelens
Department of Medical Microbiology, Ghent University Hospital, Ghent, Belgium
4 shared publications - Marc Leone
Affiliation Aix-Marseille Université, APHM, Hôpital Nord, Service d’Anesthésie et de Réanimation, Marseille, France
4 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in BMC Infectious Diseases
Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial
Background: In critically ill patients with severe infections, beta-lactam antibiotics are frequently underdosed, while studies indicate that shorter treatment durations may be sufficient when adequately dosed. The HIT-HARD trial aims to evaluate whether short-course, high-dose beta-lactam therapy is non-inferior to conventional dosing and duration in critically ill patients with severe infections. A shorter course may reduce the development of antimicrobial resistance and serve a public health benefit. Methods: The HIT-HARD trial (EU ref. 2024-514730-21-00) is a prospective, multicenter, cluster-randomized, cross-over, non-inferiority trial conducted in 14 hospitals (7 in Belgium and 7 in the Netherlands). The study aims to enroll 1,282 patients with organ dysfunction due to common infections (community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, intra-abdominal infection, or bloodstream infection). Patients treated with ceftriaxone, cefuroxime, cefotaxime, piperacillin–tazobactam, or meropenem can be included in the study. Exclusion criteria include prior study-antimicrobial therapy > 12 h for the current infection, absence of adequate source control, and infections requiring prolonged or specific dosing regimens. Participants are allocated to either the HIT-HARD strategy, a high-dose regimen (around 150–200% of standard dosing) for a short course of 3–5 days (72–120 h), or the CONTROL strategy, a conventional dosing regimen for 6–9 days (144–216 h). The primary endpoint is all-cause 90-day mortality. Secondary endpoints include mortality, recurrence of infection, antimicrobial resistance development, toxicity, antimicrobial exposure, clinical cure, resource utilization, health-related quality of life, and cost-effectiveness. Non-inferiority will be assessed using a pre-specified 7% margin by estimating the risk difference between the HIT-HARD and CONTROL groups with an unweighted cluster-level summary regression. Discussion: By determining whether this short-course, high-dose approach is non-inferior to conventional regimens, the trial has the potential to directly inform antibiotic policy and guide an evidence-based approach to safely shorten antimicrobial therapy as part of an ICU stewardship program. Trial registration: 20245147302100 (EUCT), prospective trial registration date 05DEC2024. Protocol version 3.0, protocol date 01JUN2026.
- 12 November 2026
- Published by Springer Nature in BMC Infectious Diseases
Open AccessShort-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial
Background: In critically ill patients with severe infections, beta-lactam antibiotics are frequently underdosed, while studies indicate that shorter treatment durations may be sufficient when adequately dosed. The HIT-HARD trial aims to evaluate whether short-course, high-dose beta-lactam therapy is non-inferior to conventional dosing and duration in critically ill patients with severe infections. A shorter course may reduce the development of antimicrobial resistance and serve a public health benefit. Methods: The HIT-HARD trial (EU ref. 2024-514730-21-00) is a prospective, multicenter, cluster-randomized, cross-over, non-inferiority trial conducted in 14 hospitals (7 in Belgium and 7 in the Netherlands). The study aims to enroll 1,282 patients with organ dysfunction due to common infections (community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, intra-abdominal infection, or bloodstream infection). Patients treated with ceftriaxone, cefuroxime, cefotaxime, piperacillin–tazobactam, or meropenem can be included in the study. Exclusion criteria include prior study-antimicrobial therapy > 12 h for the current infection, absence of adequate source control, and infections requiring prolonged or specific dosing regimens. Participants are allocated to either the HIT-HARD strategy, a high-dose regimen (around 150–200% of standard dosing) for a short course of 3–5 days (72–120 h), or the CONTROL strategy, a conventional dosing regimen for 6–9 days (144–216 h). The primary endpoint is all-cause 90-day mortality. Secondary endpoints include mortality, recurrence of infection, antimicrobial resistance development, toxicity, antimicrobial exposure, clinical cure, resource utilization, health-related quality of life, and cost-effectiveness. Non-inferiority will be assessed using a pre-specified 7% margin by estimating the risk difference between the HIT-HARD and CONTROL groups with an unweighted cluster-level summary regression. Discussion: By determining whether this short-course, high-dose approach is non-inferior to conventional regimens, the trial has the potential to directly inform antibiotic policy and guide an evidence-based approach to safely shorten antimicrobial therapy as part of an ICU stewardship program. Trial registration: 20245147302100 (EUCT), prospective trial registration date 05DEC2024. Protocol version 3.0, protocol date 01JUN2026.
- 2 June 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (6) , 1196-1209
Impact of appropriate antimicrobial therapy on patient outcomes and antimicrobial use: a sub analysis of the DIANA Study Dataset
Objective Although inappropriate therapy has been consistently associated with adverse outcomes, the magnitude and consistency of the benefit associated with appropriate empiric therapy in critically ill patients remain uncertain. We aimed to quantify the prevalence of appropriate empiric antimicrobial therapy and evaluate its association with outcomes and antimicrobial exposure in a large international ICU cohort. Methods This predefined sub-analysis of the DIANA study included adult ICU patients receiving empirical antimicrobials for suspected or confirmed bacterial infection. Only patients with microbiologically confirmed infections were analyzed, and therapy was classified as appropriate if at least one agent demonstrated in vitro activity against the identified pathogen. Associations with 28-day mortality and antimicrobial-free days were assessed using multivariable logistic and Cox regression models. Pre-specified interaction analyses explored effect modification by disease severity and diagnostic certainty. Results Of 845 patients with microbiologically confirmed infections, 87.7% received appropriate empirical antimicrobial therapy. Compared with inappropriate therapy, appropriate therapy was associated with significantly lower ICU mortality and longer 28-day antimicrobial-free days and mechanical ventilation-free days. After multivariable adjustment, appropriate therapy remained independently associated with reduced 28-day mortality [adjusted odds ratio (OR) 1.83, 95% confidence interval 1.11–3.06, p = 0.02; hazard ratio (HR) 1.51, 95% CI 1.03–2.21, p = 0.035]. Effect-modification analyses demonstrated that the survival benefit of appropriate therapy was consistent across levels of diagnostic certainty and was most pronounced in patients with moderate illness severity (SOFA 3–9). Conclusion In critically ill ICU patients, appropriate empirical antimicrobial therapy is independently associated with reduced 28-day mortality rates. Visual abstract The alternative text for this image may have been generated using AI.
- 2 June 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (6) , 1196-1209
Impact of appropriate antimicrobial therapy on patient outcomes and antimicrobial use: a sub analysis of the DIANA Study Dataset
Objective Although inappropriate therapy has been consistently associated with adverse outcomes, the magnitude and consistency of the benefit associated with appropriate empiric therapy in critically ill patients remain uncertain. We aimed to quantify the prevalence of appropriate empiric antimicrobial therapy and evaluate its association with outcomes and antimicrobial exposure in a large international ICU cohort. Methods This predefined sub-analysis of the DIANA study included adult ICU patients receiving empirical antimicrobials for suspected or confirmed bacterial infection. Only patients with microbiologically confirmed infections were analyzed, and therapy was classified as appropriate if at least one agent demonstrated in vitro activity against the identified pathogen. Associations with 28-day mortality and antimicrobial-free days were assessed using multivariable logistic and Cox regression models. Pre-specified interaction analyses explored effect modification by disease severity and diagnostic certainty. Results Of 845 patients with microbiologically confirmed infections, 87.7% received appropriate empirical antimicrobial therapy. Compared with inappropriate therapy, appropriate therapy was associated with significantly lower ICU mortality and longer 28-day antimicrobial-free days and mechanical ventilation-free days. After multivariable adjustment, appropriate therapy remained independently associated with reduced 28-day mortality [adjusted odds ratio (OR) 1.83, 95% confidence interval 1.11–3.06, p = 0.02; hazard ratio (HR) 1.51, 95% CI 1.03–2.21, p = 0.035]. Effect-modification analyses demonstrated that the survival benefit of appropriate therapy was consistent across levels of diagnostic certainty and was most pronounced in patients with moderate illness severity (SOFA 3–9). Conclusion In critically ill ICU patients, appropriate empirical antimicrobial therapy is independently associated with reduced 28-day mortality rates. Visual abstract The alternative text for this image may have been generated using AI.
- 25 January 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (4) , 847-853
Impact of reporting rapid susceptibility results in Gram negative bloodstream infections: a real world prospective study
Purpose Mortality and morbidity of patients with bloodstream infection (BSI) remain high despite advances in diagnostic methods and efforts to speed up reporting. This study investigated the impact of reporting rapid Minimum Inhibitory Concentration (MIC)-results in Gram negative BSIs with the ASTar system (Q-linea, Uppsala, Sweden) on the adaptation of empirically started antimicrobial therapy. We performed a real-world study during which antimicrobial susceptibility testing (AST) results were instantly reported to the treating physician in an established multidisciplinary antimicrobial stewardship setting. Methods Consecutive patients with Gram negative bacteremia were included in the study (monomicrobial Gram stain, life expectancy of at least 48 h and flagging positive before 2 PM). Rapid AST (RAST) reporting with ASTar was added on top of the standard workflow. Technical performance of the system was evaluated as well as the impact on antimicrobial treatment and timelines of achieving effective and optimal antimicrobial therapy. Results A total of 79 analyses were performed in 77 patients, of which 68 episodes were eligible for analysis. A categorical agreement was observed in 97,5% of 1160 MIC results without false susceptible results. All patients on ineffective empirical therapy (12/68) were switched after a median time of approximately one hour (5 min – 15 h) after communication of the result. Furthermore, 20/55 non-optimal therapies were adapted within a median period of 3 h after communication. Conclusion The implementation of rapid MICs, measured by the ASTar system, in our low antimicrobial resistance setting with elaborate antimicrobial guidelines, was easy and led to early adaptation of empirical treatment in 32/55 instances (12 ineffective and 20 non-optimal therapy). Trial Registration Number NCT06218277 (date of registration: 18–12-2023).
- 25 January 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (4) , 847-853
Impact of reporting rapid susceptibility results in Gram negative bloodstream infections: a real world prospective study
Purpose Mortality and morbidity of patients with bloodstream infection (BSI) remain high despite advances in diagnostic methods and efforts to speed up reporting. This study investigated the impact of reporting rapid Minimum Inhibitory Concentration (MIC)-results in Gram negative BSIs with the ASTar system (Q-linea, Uppsala, Sweden) on the adaptation of empirically started antimicrobial therapy. We performed a real-world study during which antimicrobial susceptibility testing (AST) results were instantly reported to the treating physician in an established multidisciplinary antimicrobial stewardship setting. Methods Consecutive patients with Gram negative bacteremia were included in the study (monomicrobial Gram stain, life expectancy of at least 48 h and flagging positive before 2 PM). Rapid AST (RAST) reporting with ASTar was added on top of the standard workflow. Technical performance of the system was evaluated as well as the impact on antimicrobial treatment and timelines of achieving effective and optimal antimicrobial therapy. Results A total of 79 analyses were performed in 77 patients, of which 68 episodes were eligible for analysis. A categorical agreement was observed in 97,5% of 1160 MIC results without false susceptible results. All patients on ineffective empirical therapy (12/68) were switched after a median time of approximately one hour (5 min – 15 h) after communication of the result. Furthermore, 20/55 non-optimal therapies were adapted within a median period of 3 h after communication. Conclusion The implementation of rapid MICs, measured by the ASTar system, in our low antimicrobial resistance setting with elaborate antimicrobial guidelines, was easy and led to early adaptation of empirical treatment in 32/55 instances (12 ineffective and 20 non-optimal therapy). Trial Registration Number NCT06218277 (date of registration: 18–12-2023).
- Open Access
- 13 May 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (8) , 1338-1341
Empirical antimicrobials in the intensive care unit
- 13 May 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (8) , 1338-1341
Open AccessEmpirical antimicrobials in the intensive care unit
- Open Access
- 18 March 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (6) , 873-889
The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
Purpose The primary objective of this study was to evaluate the associations between centre/country-based factors and two important process and outcome indicators in patients with hospital-acquired bloodstream infections (HABSI). Methods We used data on HABSI from the prospective EUROBACT-2 study to evaluate the associations between centre/country factors on a process or an outcome indicator: adequacy of antimicrobial therapy within the first 24 h or 28-day mortality, respectively. Mixed logistical models with clustering by centre identified factors associated with both indicators. Results Two thousand two hundred nine patients from two hundred one intensive care units (ICUs) were included in forty-seven countries. Overall, 51% (n = 1128) of patients received an adequate antimicrobial therapy and the 28-day mortality was 38% (n = 839). The availability of therapeutic drug monitoring (TDM) for aminoglycosides everyday [odds ratio (OR) 1.48, 95% confidence interval (CI) 1.03–2.14] or within a few hours (OR 1.79, 95% CI 1.34–2.38), surveillance cultures for multidrug-resistant organism carriage performed weekly (OR 1.45, 95% CI 1.09–1.93), and increasing Human Development Index (HDI) values were associated with adequate antimicrobial therapy. The presence of intermediate care beds (OR 0.63, 95% CI 0.47–0.84), TDM for aminoglycoside available everyday (OR 0.66, 95% CI 0.44–1.00) or within a few hours (OR 0.51, 95% CI 0.37–0.70), 24/7 consultation of clinical pharmacists (OR 0.67, 95% CI 0.47–0.95), percentage of vancomycin-resistant enterococci (VRE) between 10% and 25% in the ICU (OR 1.67, 95% CI 1.00–2.80), and decreasing HDI values were associated with 28-day mortality. Conclusion Centre/country factors should be targeted for future interventions to improve management strategies and outcome of HABSI in ICU patients.
- 18 March 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (6) , 873-889
Open AccessThe role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
Purpose The primary objective of this study was to evaluate the associations between centre/country-based factors and two important process and outcome indicators in patients with hospital-acquired bloodstream infections (HABSI). Methods We used data on HABSI from the prospective EUROBACT-2 study to evaluate the associations between centre/country factors on a process or an outcome indicator: adequacy of antimicrobial therapy within the first 24 h or 28-day mortality, respectively. Mixed logistical models with clustering by centre identified factors associated with both indicators. Results Two thousand two hundred nine patients from two hundred one intensive care units (ICUs) were included in forty-seven countries. Overall, 51% (n = 1128) of patients received an adequate antimicrobial therapy and the 28-day mortality was 38% (n = 839). The availability of therapeutic drug monitoring (TDM) for aminoglycosides everyday [odds ratio (OR) 1.48, 95% confidence interval (CI) 1.03–2.14] or within a few hours (OR 1.79, 95% CI 1.34–2.38), surveillance cultures for multidrug-resistant organism carriage performed weekly (OR 1.45, 95% CI 1.09–1.93), and increasing Human Development Index (HDI) values were associated with adequate antimicrobial therapy. The presence of intermediate care beds (OR 0.63, 95% CI 0.47–0.84), TDM for aminoglycoside available everyday (OR 0.66, 95% CI 0.44–1.00) or within a few hours (OR 0.51, 95% CI 0.37–0.70), 24/7 consultation of clinical pharmacists (OR 0.67, 95% CI 0.47–0.95), percentage of vancomycin-resistant enterococci (VRE) between 10% and 25% in the ICU (OR 1.67, 95% CI 1.00–2.80), and decreasing HDI values were associated with 28-day mortality. Conclusion Centre/country factors should be targeted for future interventions to improve management strategies and outcome of HABSI in ICU patients.
- 19 December 2023
- Published by Elsevier in Journal of Critical Care
- Vol. 80, 154501
Clinical outcomes in combination versus mono antibiotic therapy in ICU admitted patients with a suspected infection - A substudy of the DIANA study
- 19 December 2023
- Published by Elsevier in Journal of Critical Care
- Vol. 80, 154501
Clinical outcomes in combination versus mono antibiotic therapy in ICU admitted patients with a suspected infection - A substudy of the DIANA study
- 28 September 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (11) , 1400-1403
When fear takes control: the multidrug resistance story during pandemics
- 28 September 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (11) , 1400-1403
When fear takes control: the multidrug resistance story during pandemics
- Open Access
- 29 April 2023
- Published by Elsevier in Annals of Intensive Care
- Vol. 13 (1) , 35-17
Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study
- 29 April 2023
- Published by Elsevier in Annals of Intensive Care
- Vol. 13 (1) , 35-17
Open AccessPathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study
- 28 October 2021
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 77 (5) , 837-844
Antimicrobial prescription in severe COVID-19 and CAP: a matched case-control study
In severe coronavirus diseases 2019 (COVID-19), a high and potentially excessive use of antimicrobials for suspected bacterial co-infection and intensive care unit (ICU)-acquired infections has bee...
- 28 October 2021
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 77 (5) , 837-844
Antimicrobial prescription in severe COVID-19 and CAP: a matched case-control study
In severe coronavirus diseases 2019 (COVID-19), a high and potentially excessive use of antimicrobials for suspected bacterial co-infection and intensive care unit (ICU)-acquired infections has bee...
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 18 (5) , 830-837
Attributable Mortality of Ventilator-associated Pneumonia. Replicating Findings, Revisiting Methods
Rationale: Estimating the impact of ventilator-associated pneumonia (VAP) from routinely collected intensive care unit (ICU) data is methodologically challenging. Objectives: We aim to replicate earlier findings of limited VAP-attributable ICU mortality in an independent cohort. By refining statistical analyses, we gradually tackle different sources of bias. Methods: Records of 2,720 adult patients admitted to Ghent University Hospital ICUs (2013–2017) and receiving mechanical ventilation within 48 hours after admission were extracted from linked Intensive Care Information System and Computer-based Surveillance and Alerting of Nosocomial Infections, Antimicrobial Resistance, and Antibiotic Consumption in the ICU databases. The VAP-attributable fraction of ICU mortality was estimated using a competing risk analysis that is restricted to VAP-free patients (approach 1), accounts for VAP onset by treating it as either a competing (approach 2) or censoring event (approach 3), or additionally adjusts for time-dependent confounding via inverse probability weighting (approach 4). Results: A total of 210 patients (7.7%) acquired VAP. Based on benchmark approach 4, we estimated that (compared with current preventive measures) hypothetical eradication of VAP would lead to a relative ICU mortality reduction of 1.7% (95% confidence interval, −1.3 to 4.6) by Day 10 and of 3.6% (95% confidence interval, 0.7 to 6.5) by Day 60. Approaches 1–3 produced estimates ranging from −0.7% to 2.5% by Day 10 and from 5.2% to 5.5% by Day 60. Conclusions: In line with previous studies using appropriate methodology, we found limited VAP-attributable ICU mortality given current state-of-the-art VAP prevention measures. Our study illustrates that inappropriate accounting of the time dependency of exposure and confounding of its effects may misleadingly suggest protective effects of early-onset VAP and systematically overestimate attributable mortality.
- 1 May 2021
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 18 (5) , 830-837
Open AccessAttributable Mortality of Ventilator-associated Pneumonia. Replicating Findings, Revisiting Methods
Rationale: Estimating the impact of ventilator-associated pneumonia (VAP) from routinely collected intensive care unit (ICU) data is methodologically challenging. Objectives: We aim to replicate earlier findings of limited VAP-attributable ICU mortality in an independent cohort. By refining statistical analyses, we gradually tackle different sources of bias. Methods: Records of 2,720 adult patients admitted to Ghent University Hospital ICUs (2013–2017) and receiving mechanical ventilation within 48 hours after admission were extracted from linked Intensive Care Information System and Computer-based Surveillance and Alerting of Nosocomial Infections, Antimicrobial Resistance, and Antibiotic Consumption in the ICU databases. The VAP-attributable fraction of ICU mortality was estimated using a competing risk analysis that is restricted to VAP-free patients (approach 1), accounts for VAP onset by treating it as either a competing (approach 2) or censoring event (approach 3), or additionally adjusts for time-dependent confounding via inverse probability weighting (approach 4). Results: A total of 210 patients (7.7%) acquired VAP. Based on benchmark approach 4, we estimated that (compared with current preventive measures) hypothetical eradication of VAP would lead to a relative ICU mortality reduction of 1.7% (95% confidence interval, −1.3 to 4.6) by Day 10 and of 3.6% (95% confidence interval, 0.7 to 6.5) by Day 60. Approaches 1–3 produced estimates ranging from −0.7% to 2.5% by Day 10 and from 5.2% to 5.5% by Day 60. Conclusions: In line with previous studies using appropriate methodology, we found limited VAP-attributable ICU mortality given current state-of-the-art VAP prevention measures. Our study illustrates that inappropriate accounting of the time dependency of exposure and confounding of its effects may misleadingly suggest protective effects of early-onset VAP and systematically overestimate attributable mortality.